Resolution Therapeutics Announces Approval of Clinical Trial Application by AEMPS to Expand Phase 1/2 EMERALD Study of RTX001 into Spain
- EMERALD Study will investigate the safety and efficacy of RTX001, an engineered macrophage cell therapy, in patients with end-stage liver disease
- Recruitment already underway in the U.K., following recent MHRA approval
Edinburgh and London, UK, 19 November 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapies in inflammatory and fibrotic diseases, today announces it has received approval of a clinical trial application from the Spanish Agency of Medicines and Medical Products (AEMPS) to commence the Phase 1/2 EMERALD Study evaluating its lead candidate RTX001 in Spain.
